Browse Articles

Discover research articles across all indexed journals

ABCA1 and ABCG1 cholesterol transporters expression on metastatic renal cell carcinoma: Impact on immunotherapy outcomes (CHOMET study).

Journal of Clinical Oncology Giulia Claire Giudice, Giulia Mazzaschi, Michele Maffezzoli et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.568

568 Background: Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, most patients do not achieve benefits, emphasizing the need to understand the mechanisms of resistance. Previous analysis highlighted the association between blood cholesterol levels, passive cholesterol diffusion efflux and oncological outcomes. Here we reported the preliminary data of the CHOMET study, aimed at assessing the cholesterol transporters ABCA1 and ABCG1 expression in ICIs-treated patients with metastatic renal cell carcinoma (mRCC). Methods: The present is a monocentric retrospective study on patients with mRCC receiving first-line ICI-based combination. The primary objective was to assess the ABCA1/G1 expression by immunohistochemistry and its impact on overall survival (OS). The secondary objectives included the impact on progression-free survival (PFS) and disease control rate (DCR: complete and partial responses plus stable disease). Survival times were calculated by Kaplan-Meier method and comparisons between groups were performed by log-rank test. Results: 61 patients were enrolled, clear cell RCC was the most frequent histotype (78.8%). With a median follow-up of 30.4 months (22.1-37.0), median OS was 38.9 months (CI 33.9-NR) and median PFS was 24.4 months (CI 10.1-34.2). For the present analysis, the ABCA1/G1 histological evaluation of tumour samples was available for 43 and 41 patients, respectively. The median expression level was 50% for ABCA1 and 45% for ABCG1. We found a significant correlation between higher ABCA1/G1 staining intensity expression and both shorter median OS and PFS (Table). Similarly they were inversely related to DCR (Table). Conclusions: For the first time, we reported a high expression of ABCA1/G1 cholesterol transporter on kidney cancer. An inverse association between staining intensity expression and oncological outcomes in patients receiving ICIs combinations was found. Oncological outcomes according to ABCA1/G1 staining intensity expression. IHC mPFS months (95%CI) mOSmonths (95%CI) DCR% ABCA1 intensity expression 1+ 30.1 (25.8-NR) NR (NR-NR) 88.9 2+ 24.4 (9.9-NR) NR (33.9-NR) 72.7 3+ 4.5 (3.20-NR) 12.2 (8.2-NR) 25.0 p value 0.016 < 0.001 0.013 ABCG1 intensity expression 1+ 62.7 (25.6-NR) NR (NR-NR) 87.5 2+ 17.4 (9.9-NR) NR (NR-NR) 68.2 3+ 6.65 (2.9-NR) 12.2 (3.8-NR) 37.5 p value 0.006 0.013 0.101 DCR: disease control rate, IHC: immunohistochemistry, mOS: median overall survival, mPFS: median progression-free survival, NR: not reached.

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study.

Journal of Clinical Oncology Annalisa Guida, Alessio Gili, Claudia Mosillo et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.511

511 Background: Local therapy for managing metastatic sites may be a beneficial frontline approach for patients with mRCC. However, existing data are limited to retrospective studies involving patients treated mainly with tyrosine kinase inhibitors (TKIs). This study aims to characterize the initial LT approach prior to the initiation of immuno-TKI combinations. Methods: ProPaxi is a prospective observational study that enrolled pts treated with the Pembrolizumab/Axitinib (Paxi) combination as first-line therapy. We conducted a retrospective analysis of pts characteristics and outcomes when LT was used as a frontline approach. Results: From December 2020 to September 2023 ProPaxi study enrolled 170 pts, of whome 56 (33%) received LT as frontline therapeutic approach. The majority had clear-cell histology (86%). Approximately half of pts (46%) had synchronous metastasis and nephrectomy was performed in 60% of cases. Stratifying by IMDC criteria at the time of the start of systemic treatment, 11 pts (20%) were classified as favorable-risk, 32(59%) as intermediate-risk, and 12 (21%) as poor-risk. Additionally, around half of pts (52%) had time-to-treatment start longer than 1 year as prognostic factors; this was the only prognostic factor in 18% of cases. Bone was the most commonly treated metastatic site, accounting for 50% of cases, followed by the lung (14%) and brain (13%). The types of LT administered were as follows: radiotherapy (46%), surgery (43%), and other (11%). The objectives of treatment included: pain control (30%), curative treatment for local complications (29%), prevention of local complications (29%), and achieving complete response or delaying systemic treatment (30%). In one-fifth of patients (21%), there were multiple objectives for the local therapy. Radiotherapy was the most frequently used treatment for pain control, applied in 94% of cases. For managing local complications, surgery and radiotherapy were also common, accounting for 31% and 38%, respectively. Both treatments were equally utilized (38%) for the prevention of local complications. Surgery was the predominant approach for achieving complete response or delaying systemic treatment, used in 88% of cases. The mean time from metastasis diagnosis to treatment start was 7.9 months (95% CI: 4.1–11.2) for patients who received LT versus 2.5 months (95% CI: 1.9–3.1) for those who did not (p < 0.001). No significant differences were observed in progression-free survival (PFS) or overall survival (OS). Conclusions: This analysis describes for the first time the current approach to implementing LT for the management of mRCC. Thus, LT emerges as a valid and established option even in the era of immuno-TKI combinations. The objective of therapy appears to be the key factor in determining the choice of treatment in clinical practice.

Where is communication breaking down? Narrative tensions in obesity-in-pregnancy clinical encounters

PLoS ONE Rachel Dadouch Enzel, Sarenna Lalani, Rory Windrim et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318514

There are numerous biomedical and psychosocial challenges associated with obesity in pregnancy that impede communication between healthcare providers (HCPs) and patients. We conducted a narrative study informed by stigma theory to understand specific areas of communication breakdown in obesity-in-pregnancy clinical encounters. Sixteen patients and 19 HCPs participated in in-depth, semi-structured interviews. We explored how participants positioned obesity-in-pregnancy clinical encounters within their broader narratives. Employing narrative analysis, we identified five narrative tensions contributing to communication challenges: 1) obesity as a detriment to health versus an acceptable biologic variation ; 2) obesity as the result of personal choice versus the result of uncontrollable circumstances ; 3) a regular pregnancy versus a high-risk diagnosis; 4) a typical and problem-free clinical encounter v ersus a tremendously difficult clinical encounter ; and 5) talking openly about Body Mass Index (BMI) and related co-morbidities versus sidestepping the topic . How participants positioned themselves relative to prevailing societal discourses regarding obesity in general influenced these tensions. These narrative tensions revealed specific areas where communication is vulnerable to breaking down during the obesity-in-pregnancy clinical encounter. Participants’ (both HCPs and patients) past experiences of clinical encounters–and the meanings they ascribe to them–shape subsequent encounters, and our analysis illuminates the complexities of this interactive space. This research has implications for improving clinical practice and education.

Mangroves, fauna compositions and carbon sequestration after ten years restoration on Flores Island, Indonesia

Scientific Reports Pandu Y. A. P. Wirabuana, Liliana Baskorowati, Bayu Pamungkas et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87307-x

Somatic genomic landscape of prostate adenocarcinoma at a comprehensive cancer center in New Mexico: A retrospective study (2015-2022).

Journal of Clinical Oncology Mahmoud Abdelsamia, Daniel Joseph Chavarin, Jonathan Coy et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.200

200 Background: Prostate cancer is the second leading cause of cancer-related deaths in men. In New Mexico, it is the leading cause of cancer death among specific populations, particularly American Indians and African Americans. This study investigates the frequency and diversity of somatic mutations in patients with prostate adenocarcinoma treated at the University of New Mexico Comprehensive Cancer Center (UNMCCC). Methods: We conducted a retrospective analysis of patients with prostate adenocarcinoma treated at UNMCCC from 2015 to 2022 who underwent screening for somatic mutations via next-generation sequencing (NGS). We evaluated these mutations and collected data on tissue type tested, race, ethnicity, and age. Descriptive analysis summarized frequencies of somatic mutations overall and across ethnic groups. Due to small sample sizes, randomization tests were performed to evaluate whether mutation rates within ethnic groups differed significantly from those expected based on the ethnic composition of the entire sample. Results: The study examined 61 patients (median age 63 years) including: 31 White (51%), 16 Hispanic (26%), 9 American Indian (15%), 4 African American (7%), and 1 Asian (2%). Of the patients tested, 52 underwent tissue-based NGS, 7 had liquid-based NGS, and 2 had both tests performed. The most prevalent genetic alterations were TMPRSS2-ERG fusion (48%), TP53 mutations (41%), PTEN loss/rearrangement (36%), and AR mutations (30%). Comparisons of mutation frequencies across ethnic groups revealed variations in mutation prevalence (Table 1) For most mutations, observed ethnic group frequencies did not differ significantly from expected frequencies based on the total sample (p>0.05), although statistical power was low to detect all but large differences. The exception was BRCA2, where ethnic group frequencies differed significantly from those in the total sample (p=0.025), with no Hispanic patients and equal numbers of White and Native American patients having the mutation. Conclusions: This study reveals complex prostate cancer genetic patterns across diverse New Mexican ethnicities. These findings have potential implications for targeted therapies and emphasize the need for larger, more diverse cohorts in research. Proportion of race and ethnic groups with each mutation. Mutation Number Positive Proportions Within Racial/Ethnic Groups Hispanic Native American Black White Asian TMPRSS2:ERG fusion 29 24.1% 17.2% 0.0% 55.2% 3.4% TP53 25 24.0% 8.0% 8.0% 60.0% 0.0% PTEN loss/frameshift 22 27.3% 13.6% 4.5% 54.5% 0.0% AR Mutations 18 27.8% 5.6% 5.6% 61.1% 0.0% MYC amplification 11 45.5% 9.1% 0.0% 45.5% 0.0% PIK3CA 7 28.6% 28.6% 0.0% 42.9% 0.0% RAD51 R/RAD21 AMP 7 57.1% 14.3% 0.0% 28.6% 0.0% BRCA2 6 0.0% 33.3% 16.7% 33.3% 16.7% BRCA1 3 66.7% 0.0% 0.0% 33.3% 0.0% ATM 3 0.0% 33.3% 0.0% 66.7% 0.0% All Screened 61 26.2% 14.8% 6.6% 50.8% 1.6%

Artificial intelligence–derived tumor volume from baseline MRI and postprostatectomy outcomes following neoadjuvant hormonal therapy for patients with high-risk prostate cancer.

Journal of Clinical Oncology David Yang, Leslie K Lee, Praful Ravi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.330

330 Background: Neoadjuvant hormonal therapy (NHT) with androgen deprivation therapy and androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) has emerged as a potentially promising strategy for patients with high-risk prostate cancer (PCa), with several trials, including PROTEUS, which are investigating this approach. Early studies demonstrated that 20-25% of patients have a pathologic complete response (pCR) or minimal residual disease (MRD) after NHT with ARPI, which is highly prognostic for long-term outcomes. However, predictors of pCR/MRD remain poorly understood. We previously demonstrated that the total volume of intraprostatic tumor (V AI ) on prostate multiparametric MRI, determined using an artificial intelligence (AI) model, is independently prognostic in localized PCa treated with upfront RP or radiotherapy. Our objective was to examine the association between pre-NHT V AI and outcomes after RP. Methods: We identified 105 patients with high-risk PCa from 4 prospective trials of NHT with ARPI who had pre-NHT MRIs between 2009-2018. A deep learning model for segmenting the intraprostatic tumor was trained using nnU-Net v2 with a ResNet encoder with an independent cohort of 1776 patients with localized PCa and MRIs utilizing 5-fold cross-validation. An ensemble model was used to provide segmentations for held-out pre-NHT MRIs. We examined the association between V AI and likelihood of pCR/MRD (≤5mm residual tumor) using logistic regression, as well as associations between V AI and time to next therapy (TT) and metastasis-free survival (MFS) using univariable Cox regression. Results: 26 patients (24.7%) had pCR/MRD. Median pre-NHT V AI for patients with and without pCR/MRD were 0.87mL (interquartile range [IQR] 0.25-1.53) and 2.50mL (IQR 1.16-4.30), respectively. Increasing V AI was associated with decreased likelihood of pCR/MRD on multivariable analysis (adjusted odds ratio 0.97 per mL increase, 95% confidence interval [CI] 0.95-1.00, p=0.027). V AI had a greater area under the receiver operating characteristics curve than NCCN clinical risk groups (0.778 vs 0.511, p<0.001) for predicting pCR/MRD. After median follow-up of 6.3 years, the hazard ratios for associations between V AI and TT and MFS were 1.14 (95% CI 1.08-1.21, p<0.001) and 1.07 (95% CI 0.99-1.16, p=0.091), respectively. 6-year MFS rates were 94.4%, 87.0%, and 75.4% for V AI of 0-0.4, 0.5-1.9, and ≥2.0mL, respectively. Conclusions: A higher V AI on baseline MRI was associated with decreased likelihood of pCR/MRD and shorter time to next therapy after NHT and RP. If validated, AI-determined tumor volume has potential for becoming a clinically useful tool for the upfront identification of both patients most likely to benefit from NHT and RP, as well as those who should be considered for alternative treatment strategies.

Burden of cancer in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology Dena Battle, Meghan Griffith, Pavlos Msaouel et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.467

467 Background: Combination regimens and sequencing of multiple agents have significantly improved clinical outcomes for patients (pts.) with mRCC. We sought to assess the burden of mRCC on patients and interference with daily life. Methods: The survey was developed by the Kidney Cancer Research Alliance (KCCure), and broadcast between 09/24 and 10/24 to pts. via website, mailing lists and social media platforms. Results: Of 1167 respondents, 492 pts. had received systemic therapy for mRCC. Median age was 58.7 years (range 17.2 - 87.0), 83% were from the United States. 42% were on first line treatment, 30% second line, 13% third line, and 15% in fourth or later line. 69% were on systemic on therapy with evidence of disease, 10% were receiving treatment with no evidence of disease, 13% had discontinued treatment with no evidence of disease; 8% had discontinued treatment with evidence of metastatic disease. 45% of pts. take ≥7 prescriptions per day, 11% take ≥10 prescription medications per day. One-third (33%) of pts. are concerned they are taking too many medications. In the last year, pts reported seeing 4.24 (range 1-17) different types of doctors for cancer related care. In the last 90 days: 36% have gone to the emergency room, 20% more than once. 96% had blood drawn at least once, 35% had ≥5 blood draws. 95% had at least one clinic visit, 22% ≥5 clinic visits. 30% had ≥5 pharmacy visits. 23% have been hospitalized, 12% for ≥5 days. In the last year, 45% were hospitalized at least once, 52% more than once, 11% ≥5 times. Hospitalizations and visits to the emergency room were significantly correlated with a lower quality of life and higher NCCN distress score (p<.001). 89% of pts think about cancer every day; 44% spend a few to several hours per day thinking about cancer. When asked how confident they feel about making plans, 33% feel completely confident making plans 6 months from now, 21% one year and 10% two years from now. Pts. with no evidence of disease are significantly more likely to rank their QOL as excellent (19%) compared to pts. with evidence of disease (4%), independent of treatment. Pts. who have discontinued treatment and still have evidence of disease rank their QOL as poor (17%). Conclusions: Pts. living with mRCC are physically and mentally consumed with cancer and disease management. mRCC disrupts fundamental daily activities, including eating, sleeping, and socializing. Pts. must routinely engage with the healthcare system, extensively managing scheduled and unscheduled appointments with multiple providers. Nearly all contemplate their cancer daily. More research is needed to improve care and alleviate disease burden in mRCC. Disruption of daily and routine activities. Activities Impacted by Cancer Frequency - Always or Often Eating a meal 37% Sleeping 38% Engaging with Friends 31% Grocery Shopping 25% Attending an Event 31% Buying Clothes 18% Traveling 43%

Association between baseline and changes in hemoglobin levels and treatment response and prognosis in metastatic renal cell carcinoma: A Mexican retrospective study.

Journal of Clinical Oncology Saul Campos Gomez, Sandra Vargas Melendez, Arturo Gonzalez Santana Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.518

518 Background: Clinical markers of response and outcome in metastatic renal cell carcinoma (mRCC) are lacking. Low hemoglobin (Hb) is associated with poor outcomes in the IMDC risk score. Hb levels also appear to be associated with mRCC response to VEGFI monotherapy, although this relationship is nuclear. This study evaluates the role of Hb increases as a predictive biomarker of clinical response and outcomes. Methods: Patients with advanced RCC treated with VEGF receptor tyrosine kinase inhibitors (TKIs) as a first-line therapy were identified. Hemoglobin levels were retrieved at baseline and then at monthly intervals for 6 months. Absolute and percentage increases over baseline were evaluated as predictors of objective response rate, progression free survival. Patients were categorized as responders (CR+PR) or nonresponders (SD+PD) using cross-sectional imaging at week 12. The Kaplan-Meier method was used to estimate PFS for patients who had an increase vs. decrease from baseline Hb, and the log-rank test used to assess survival differences between the groups. The Cox proportional hazards model was used for univariate and multivariate regression analysis to determine the significance of individual variables on PFS. Results: Among the 47 eligible patients, elevations in hemoglobin were observed in 64%. The median age at start of treatment was 59 years. Changes in hemoglobin at time of response were associated with objective response rate. Landmark analysis at 1 month showed that increases in hemoglobin were associated with longer PFS (mPFS 15 vs. 50 months; P = .004) Responders had a significantly higher Hb level than nonresponders at 1rs month P= 0.004. An increase in Hb was a significant independent predictor of progression-free survival (HR 0.47, P= .039). Conclusions: In this retrospective clinical study, we demonstrate that Hb levels are a valuable clinical marker of outcomes in patients receiving first-line therapy for mRCC in our population. These findings are readily applicable to routine clinical practice and may help clinicians deliver more personalized care.

Does patients’ age predict their clinical outcomes following non-infectious epiglottitis? A systematic review

PLoS ONE Alaa Safia, Uday Abd Elhadi, Rabie Shehadeh et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318648

Background Non-infectious epiglottitis, an infrequent but significant condition, presents challenges in airway management and treatment due to its potential for rapid progression. Objective To analyze differences in clinicodemographic characteristics, management strategies, and clinical outcomes between pediatric and adult cases of non-infectious epiglottitis. Methods A systematic search of four databases identified 57 patient records, all diagnosed with non-infectious epiglottitis. Children (<18 years) were compared to adults (≥18 years). Differences in clinicodemographic characteristics, management strategies, and clinical outcomes were analyzed. Outcomes included intubation, complications, and intensive care unit (ICU) admission. Risk factors of these outcomes were identified through uni- and multi-variable logistic regression analyses. Results Twenty-three children and 34 adults were analyzed. The presentation with stridor (56.52% vs. 14.7%), drooling (56.52% vs. 26.47%), cyanosis (17.39% vs. 0%), and sternal retraction (13.04% vs. 0%) was more common among children. Prior vaccination was evident in only 5 pediatric cases. The etiology of epiglottitis was similar across groups. Children had significantly higher chances of receiving epinephrine (34.78% vs. 8.82%), undergoing intubation (82.60% vs. 20.58%), being admitted to the ICU (56.52% vs. 17.64%), and having complications (47.82% vs. 14.70%), compared to adults. In the multivariate regression model, pediatric age was a risk factor for intubation (p = 0.015) and ICU admission (p = 0.040), while foreign body ingestion (p = 0.039) and dyspnea (p = 0.014) were predictors of intubation and complications, respectively. Conclusions The study highlights the necessity for age-specific management strategies in non-infectious epiglottitis. Understanding the distinct clinical presentations and responses in different age groups can lead to improved patient care.

Influence of biochar on the partitioning of iron and arsenic from paddy soil contaminated by acid mine drainage

Scientific Reports Chipeng Zhang, Jianglan Luo, Wansheng Song et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89728-0

Daily briefing: How did childhood evolve?

Nature Flora Graham Feb 10, 2025 DOI: 10.1038/d41586-025-00440-5

Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Journal of Clinical Oncology Martin Zarba, Dylan O'Sullivan, Razane El Hajj Chehade et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.479

479 Background: Cabozantinib is approved as a subsequent therapy for patients with metastatic renal cell carcinoma (mRCC) based on the METEOR trial. However, only 5% of patients in this trial received prior immunotherapy. Methods: We identified patients with mRCC from the IMDC who were treated with cabozantinib in the second-line (2L) setting from 2010 to 2023. These patients were stratified by IMDC risk groups and first-line (1L) treatment. We analyzed overall response rate (ORR), time to next treatment (TTNT), treatment duration (TD), overall survival (OS) and performed a multivariable analysis adjusted by IMDC criteria at 2L. Results: A total of 603 patients were identified. Baseline characteristics are summarized in the table. For the entire cohort, the ORR was 25.7%, TTNT was 10.1 months (mo), TD was 8.9 mo and mOS was 19 mo. Among patients treated with 1L ipilimumab/nivolumab (n=190), anti-PD1 + TKI (n=148), and TKI alone (n=207), cabozantinib showed an ORR of 27.2%, 26.4%, and 25%, respectively; a median TTNT of 9.9, 10.3, and 9.7 mo; a median TD of 9.4, 8.2, and 8.3 mo. Median OS was 18.6, 17.6, and 21.3 mo, respectively. A multivariable analysis was unable to demonstrate that first-line ORR (CR/PR vs SD vs PD) or TTNT (< 12 vs ≥ 12 mo) predicts for second-line cabozantinib ORR in the overall cohort and by first-line therapy type. Specifically, patients with stable disease or with partial and complete response in 1L were associated with an OR for a response of 0.99 (95% CI 0.52-1.92) or 1.23 (95% CI 0.61-2.49), respectively. Similarly, a first-line TTNT of ≥12 months had an OR for response of 1.04 (95% CI 0.59-1.82). Conclusions: This study demonstrates that cabozantinib maintains efficacy comparable to that observed in the METEOR trial in a real-world setting, including in patients with prior immunotherapy combination therapies. Efficacy of 1L treatment does not predict efficacy of 2L cabozantinib. Baseline characteristics. Variable Overall (N = 603) IO-IO (N = 190) IO-TKI (N = 148) TKI Alone (N = 207) Other (N = 58) p-value Non clear cell histology 107 (17.7) 33 (17.4) 26 (17.6) 28 (13.5) 20 (34.5) 0.003 Nephrectomy 416 (69.0) 97 (51.1) 110 (74.3) 166 (80.2) 43 (74.1) <0.001 1st line IMDC Risk Fav/Int/Poor 83 (13.8)/296 (49.1)/101 (16.7) 10 (5.3)/100 (52.6) /46 (24.2) 37 (25)/62 (41.9) /20 (13.5) 29 (14)/99 (47.8)/27 (13) 7 (12.1)/35 (60.3)/8 (13.8) <0.001 2nd line IMDC risk Fav/Int/Poor 56 (9.3)/269 (44.6)/108 (17.9) 7 (3.7)/90 (47.4)/45 (23.7) 25 (16.9)/63 (42.6)/24 (16.2) 19 (9.2)/87 (42.0)/32 (15.5) 5 (8.6)/29 (50.0)/7 (12.1) 0.002 Greater than 1 site of Metastasis 473 (78.4) 146 (76.8) 114 (77.0) 161 (77.8) 45 (77.6) 0.722 Brain Metastasis 36 (6.0) 18 (9.5) 5 (3.4) 13 (6.3) 0 (0.0) 0.022 Bone Metastasis 221 (36.7) 74 (38.9) 60 (40.5) 70 (33.8) 17 (29.3) 0.326 Liver Metastasis 106 (17.6) 32 (16.8) 26 (17.6) 39 (18.8) 9 (15.5) 0.926

Utility of post-treatment SPECT/CT for identifying disease progression in patients with mCRPC treated with <sup>177</sup> Lu-PSMA-617.

Journal of Clinical Oncology Miguel Muniz, Alton Oliver Sartor, Jacob Orme et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.114

114 Background: Oncologists have traditionally relied upon serial assessments of PSA and periodic imaging (i.e., every 2 to 3 cycles) to monitor treatment response. Early identification of disease progression allows for faster transitions to alternative therapies that might be more effective. In this study, we evaluated the utility of post-treatment SPECT/CT for earlier detection of treatment failure in patients receiving Lutetium-177–PSMA-617 (LuPSMA). Methods: We queried an IRB-approved registry including all patients starting LuPSMA at Mayo Clinic, MN, in the interval of March 2022 to March 2023. Those receiving fewer than 2 cycles of treatment and missing SPECT/CT data were excluded. We reviewed clinical notes to document the date and reason(s) for treatment discontinuation. The assembled cohort consists of patients stopping LuPSMA for progressive disease ([PD], categorized as biochemical, radiographic, or both). Results of the prior SPECT/CT imaging reports were reviewed. At our institution SPECT/CT images are typically acquired on the day after each infusion. Metrics collected from the radiology reports included: new foci of PSMA localization since the prior PSMA PET or SPECT/CT, suspicion for new non-PSMA avid disease, and a visual determination of PSMA-avid tumor volume. Results: A total of 256 patients received an initial cycle of LuPSMA. SPECT/CT imaging data for at least 2 consecutive treatment cycles was available for 68 patients who developed PD after a median (IQR) of 3 (2-4) cycles. There were 55 patients (81%) with both biochemical and radiographic evidence of PD, 7 (10%) with biochemical only progression, and 6 (9%) with radiographic only progression. The most used imaging modality for response assessment was PSMA PET/CT (n=46, 67%), followed by conventional imaging (n=9, 13%), and choline PET/CT (n=5, 7%). The median time between most recent post-therapy SPECT/CT and determination of PD was 39 days. The prior SPECT/CT had detected new foci of PSMA avid disease in 12 (18%) cases and new non-PSMA avid disease in 5 (7%) cases. Two patients had both new PSMA-avid and non-PSMA avid lesions. The most common sites of new PSMA-avid disease on SPECT/CT were bone (n=10) and liver (n=2). A total of 20 (29%) patients had visually increased tumor volume on SPECT/CT, 9 (45%) of which had no new lesions. In total, 24 of 68 patients (35%) had early detection of treatment futility detected by SPECT/CT. At a median (IQR) follow-up time of 8 (6.4-12) mo, the median OS [95% CI] was similar for patients with PD detected on SPECT/CT (7.8 [6.6 – 9] mo) compared to those without clear evidence of PD on SPECT/CT(8.4 [6.4-10.3] mo, p=0.885). Conclusions: Post-treatment SPECT/CT imaging may complement traditional forms of response assessment and provide an earlier warning of treatment failure through identification of new PSMA-avid lesions, non-PSMA avid disease, and increased tumor volume.

Racial and ethnic disparities in urinary continence recovery post-prostatectomy.

Journal of Clinical Oncology Austin Drysch, Conor Driscoll, Adam B Murphy et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.376

376 Background: Urinary incontinence is a common complication following prostatectomy, with continence recovery rates varying widely across the literature. While 12-month continence rates are consistently above 90%, disparities in short- and intermediate-term recovery rates exist. This study investigates the differences in overall urinary continence outcomes among Black, non-Black Hispanic, and non-Black non-Hispanic men within 12 months post-surgery. Methods: Data were collected from two sources: (1) men recruited in clinic from the Northwestern University Department of Urology as part of the URO-QOL study, an observational study of Quality Of Life (QOL), and (2) cross-sectional, retrospective data from an online health panel maintained by OP4G (Opinions 4 Good, http://op4g.com/). Eligible participants had clinically localized prostate cancer, were 18 years or older, and were able to read and speak English. Urinary continence outcomes were assessed within 12 months post-surgery using the American Urological Association Symptom Score (AUASS), Expanded Prostate Cancer Index Composite-26 (EPIC-26), and Functional Assessment of Cancer Therapy-Bladder (FACT-Bl). One-way ANOVA, as well as Chi-squared tests, were performed to assess differences in functional outcomes across racial and ethnic groups. Results: There were 417 patients total, with 57 (14%) Black men, 87 (21%) non-Black Hispanic men, and 273 (65%) non-Black non-Hispanic men.One-way ANOVA demonstrated significant differences in overall AUA Symptom Score (p=0.0166) and EPIC-26 Urinary Symptom Score (p=0.00276), but not FACT-Bl Scores (p=0.253), between Black, non-Black Hispanic, and non-Black non-Hispanic men, with Black men demonstrating highest symptom burden across all three surveys (Table). Conclusions: Racial and ethnic disparities in urinary continence recovery following radical prostatectomy are evident, with Black men in particular experiencing worse outcomes compared to Hispanic and non-Black non-Hispanic men. While overall functional recovery improves within 12 months post-surgery, these disparities suggest a need for further investigation into underlying factors influencing these outcomes. Ultimately, targeted pre- and post-operative interventions such as pelvic floor muscle training may help mitigate the racial and ethnic disparities highlighted in this study. Univariate ANOVA analysis of summed scores of post-treatment urinary symptoms surveys. Overall Black Non-Black Hispanic Non-Black Non-Hispanic P-value AUASS Sum (mean) 21.40 23.32 22.95 20.48 0.0166* Category (mean) 2.556 2.737 2.628 2.494 0.0137* EPIC-26 Sum Urinary Symptom Responses (mean) 19.96 22.78 20.92 19.07 0.00179* Overall Urinary Symptom Score^ (mean) 50.584 42.644 48.109 53.053 0.00276* FACT- Bl Sum (mean) 8.856 9.302 9.076 8.678 0.253 *p&lt;0.05 denotes statistical significance. ^Lower EPIC-26 score represents higher symptom burden.

Impact of belzutifan on anemia and hypoxia in sporadic and <i>VHL</i> -syndrome-associated renal cell carcinoma.

Journal of Clinical Oncology Paulo Siqueira do Amaral, Aaron Winer, Katy Beckermann et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.522

522 Background: Inactivation of the tumor suppressor von Hippel-Lindau ( VHL ) gene is associated with VHL -syndrome-associated renal cell carcinoma ( VHL- RCC) and sporadic renal cell carcinoma (spRCC). The inactivation of the VHL results in the accumulation of HIF-2a, promoting the expression of genes involved in angiogenesis and cycle-cell progression. Belzutifan, a HIF2α inhibitor, is approved for the treatment of VHL -RCC and spRCC patients (pts). Understanding the safety differences of belzutifan in these two populations can inform clinical management. Methods: This is a single-center, retrospective analysis of pts with spRCC and advanced VHL- RCC treated with belzutifan monotherapy between November 2018 and August 2024. The study population was separated into groups based on RCC type: spRCC and VHL- RCC. Demographic and clinical data were collected from medical records. The primary endpoints were the incidence of anemia and hypoxia. Continuous variables were reported as median with interquartile ranges (IQR) and compared using Wilcoxon rank-sum test. Categorical variables were presented as frequencies and percentage, with group comparisons performed using the Pearson Chi-Square test. Results: Pts with spRCC were older than those with VHL -RCC pts, with a median age of 67 y vs 41 y (p&lt; 0.001), and were predominantly male, (68% vs 36%, p = 0.035). Reduced glomerular filtration rate (defined as &lt; 50ml/min), was more prevalent in spRCC pts (36.5% vs 4.5%, p = 0.009). Baseline hemoglobin levels were similar between groups 13 g/dL (IQR: 10 – 14) vs.13 g/dL (IQR: 12.8 – 14.8). VHL- RCC pts received belzutifan for longer duration than spRCC pts (30.9 m vs 3.4 m, p &lt; 0.001). In terms of safety, any-grade and Grade 3 anemia were similar between groups, 82% vs 91% (ns) and 54% vs 36% (ns), respectively. However, anemia developed more rapidly in spRCC pts, 29 d vs. 82 d (p &lt;0.01) for any-grade, and 46 d vs. 104 d (p = 0.018) for grade 3 anemia. The need for blood transfusion was more frequent in spRCC patients (18% vs 0%, p &lt; 0.05) as was the use of erythropoietin-stimulating agents 2% vs 4.5%, p = 0.08). Any-grade hypoxia was more frequent in spRCC pts (59% vs 18%, p 0.005), and there was a trend towards more grade 3 hypoxia (54.5% vs 9%, p = 0.052). Grade 3 hypoxia developed faster in spRCC pts (29 d vs 225 d, p = 0.039), the need for oxygen was more frequent in this population (52.5% vs 9.5%, p =0.003). Treatment discontinuations were more frequent in spRCC pts than in the VHL -RCC pts, 36.4% vs 4.5% (p = 0.009), 75% of discontinuations in spRCC were due to toxicity. Conclusions: Our cohort demonstrates differences in the safety profile of belzutifan between spRCC and VHL -RCC patients. These findings underscore the importance for personalized monitoring and management for each patient population.

Bivariate multilevel modeling of antenatal care contacts and place of delivery among reproductive-aged women in Ethiopia

PLoS ONE Denekew Bitew Belay, Seniat Mulat, Nigussie Adam Birhan et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0316795

Background Antenatal care (ANC) contacts, along with enhanced health facilities for delivery, are essential components of maternal and child healthcare, as these significantly contribute to both mothers and their newborn child’s health. Antennal care contacts primarily help women maintain normal pregnancies by detecting pre-existing conditions and preventing complications that may arise during childbirth. This study intended to determine possible factors that affect both ANC contact and place of delivery among women in Ethiopia. Methods The 2019 Ethiopian Mini Demographic and Health Survey data were used for this study. A total weighted sample of 3,926 women nested within 68 zones was used. The bivariate multilevel logistic regression model was utilized to assess the association between antenatal care contact and place of delivery and determinant factors among reproductive-aged women in Ethiopia. Results In this study, 57% and 47.5% of women had no ANC contacts and home delivery respectively. Similarly, about 36.73% of women delivered at home and didn’t utilize the recommended ANC contacts. Only 32.99% of women have both health facility delivery and at least four ANC contacts during their pregnancy. Women who reside in rural areas were 0.612 and 0.352 times less likely to have ANC and health facility delivery compared to women who reside in urban areas. Whereas, the estimated odds of women with higher education levels were 3.803 and 8.406 times the estimated odds of women with no education. Conclusion A high proportion of women are still delivering their new child at home and still don’t have at least four ANC contacts during their pregnancy. Women’s age, women education level, marital status, wealth status, sex of household head, place of residence, and region were significant predictors of antenatal care visits and place of delivery simultaneously in Ethiopia. Although the country tried to maximize these services, it still requires expansion of health facilities media campaigns, and women’s literacy to reduce maternal and newborn child mortality in Ethiopia.

Minimizing makespan for mixed batch scheduling with identical machines and unequal ready times

Scientific Reports JinDian Huang Feb 10, 2025 DOI: 10.1038/s41598-025-89698-3

Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study.

Journal of Clinical Oncology Javier Puente, Jose García Sánchez, Joan Folqué et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.142

142 Background: Darolutamide, enzalutamide or apalutamide have demonstrated to prolong overall survival in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Despite their effectiveness, almost all patients progress to mCRPC. In the last few years, several new options for treatment of advanced prostate cancer have shown survival benefit. Darolutamide showed significantly prolonged metastasis-free survival compared with placebo in patients with nmCRPC in ARAMIS phase III trial. There is a lack of data about treatment patterns of patients that progress after receiving darolutamide in nmCRPC in the real-world setting in this new scenario with so many treatments available. Methods: This is a retrospective, observational, multicenter, longitudinal follow-up study to describe the treatment patterns received by the Spanish patients who received darolutamide in the ARAMIS study, according to standard clinical practice in Spain. This study involved at Urology and Oncology Departments of 18 selected hospitals. Results: Eighty-five patients were included in the study; median age was 76 years; 49 patients (58%) progressed to mCRPC and, of these, 35 (71%) received treatment for mCRPC; median number of lines post-progression was 2 (range 1-5). Abiraterone (22/35 [63%]) and docetaxel (10/35 [29%]) were the most commonly used drugs in the first line, docetaxel (12/21 [57%]) and cabacitaxel (12/21 [19%]) in the second line and cabacitaxel (4/12 [33%]) and docetaxel (3/12/21 [25%]) in the third line. Eleven patients received palliative radiotherapy (11/35 [31%]) and 7 (7/35 [20%]) osteoclast targeted therapy (5 zoledronate and 2 denosumab) after darolutamide. Conclusions: The results show that 29% of patients who progressed to mCRPC do not receive treatment after darolutamide and of those receiving treatment, 63% receive abiraterone, which appears not to be in line with current European guidelines. Only one-fifth of patients receive osteoclast targeted therapy, which is clearly insufficient. The variability in the duration of treatments and sequences suggests a lack of consensus in Spanish clinical practice. It is critical to explore more standardized strategies to maximize treatment effectiveness in these patients.

Exploring social vulnerability in prostate cancer management: Insights into utilization of watchful waiting and active surveillance from 1998 to 2017.

Journal of Clinical Oncology Nana Shakhnazaryan, Jenna Winebaum, Lufan Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.322

322 Background: Active surveillance (AS) and watchful waiting (WW) represent different conservative management strategies for prostate cancer (PCa), with AS being the preferred strategy. The Social Vulnerability Index (SVI) is enhancing our understanding of healthcare treatment disparities and social risk factors in the cancer care, but its impact in prostate cancer care remains unclear. We examine how social vulnerability influences the choice of WW vs AS in managing men with low and intermediate risk prostate cancer. Methods: The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database was used to identify men diagnosed with localized, low, and intermediate-risk prostate cancer (i.e., those potentially eligible for active surveillance) from 1998 to 2017. Participants' data were geocoded and de-identified, then combined with Social Vulnerability Index (SVI) data, which is based on four themes: socioeconomic status, household composition, minority status, and housing &amp; transportation. We used multinomial logistic regression to examine the association between SVI and conservative management strategies of WW and AS. Results: Among 681 low-risk and intermediate-risk prostate cancer patients diagnosed from 1998 to 2017, 135 were assigned to watchful waiting (WW) and 546 to active surveillance (AS), reflecting a trend toward AS. The mean Social Vulnerability Index (SVI) was higher in the WW group (0.30) than in the AS group (0.21). Significant differences were noted by Socioeconomic Status (0.33 vs 0.15, p = 0.02). Conclusions: For patients with low and intermediate risk localized prostate cancer higher SVI, particularly in communities with greater socioeconomic challenges and higher proportion of racial while the overall proportion of AS increased over time. Our findings underscore how patients with higher SVI may experience considerable undertreatment, even with the concomitant increase in AS utilization over time. Identifying these communities remains a crucial step in addressing local drivers of treatment disparities in PCa care.

Cabozantinib as subsequent therapy to an immune checkpoint-based therapy in renal cell carcinoma, phase 2 interventional study (AT ASIA, KCSG GU21-02).

Journal of Clinical Oncology Jae Lyun Lee, Sang Joon Shin, Inkeun Park et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.547

547 Background: Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of advanced renal cell carcinoma (aRCC). However, many patients develop disease progression, underscoring the need for effective second-line therapies. The optimal sequencing after ICI-based treatment remains under investigation. This phase II study evaluates the efficacy and safety of cabozantinib in patients with aRCC who progressed on first-line ICI combination therapies. Methods: This multicenter, prospective, phase II trial enrolled patients with advanced RCC who had progressed after receiving either nivolumab plus ipilimumab (Cohort 1) or a PD-1/PD-L1 inhibitor in combination with a VEGFR-TKI (e.g., pembrolizumab plus axitinib or pembrolizumab plus lenvatinib; Cohort 2). Non-clear cell histology was allowed in Cohort 2. Eligible patients were treated with cabozantinib at standard dosing. The primary endpoint was objective response rate (ORR) per RECIST 1.1 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: From September 2021 to August 2024, 88 patients (Cohort 1, n=49; Cohort 2, n=39) were enrolled across 13 institutions. The baseline International Metastatic RCC Database Consortium (IMDC) risk categories were as follows: favorable (15.9%), intermediate (71.6%), and poor (12.5%). Prior nephrectomy was reported in 42.0% of patients, and non-clear cell histology accounted for 20.5% of Cohort 2. After a median follow-up of 18.3 months (95% CI, 11.3–25.3), the ORR was 47.7%. Partial responses were observed in 51.0% (95% CI, 40.1–61.5) of patients in Cohort 1 (ICI-ICI) and 43.6% (95% CI, 30.5–56.8) in Cohort 2 (ICI-VEGFR-TKI). Stable disease was achieved in 43.2% of patients overall. The median PFS was 7.9 months, with a PFS of 9.2 months (95% CI, 6.6–11.8) in Cohort 1 and 7.1 months (95% CI, 6.7–7.6) in Cohort 2. No significant difference in OS was observed between the cohorts, with a 12-month OS rate of 65.2%. Safety analysis revealed no novel adverse events beyond the known cabozantinib toxicity profile, with grade 3/4 hypertension, hand-foot syndrome, and fatigue being the most commonly reported events. Conclusions: Cabozantinib demonstrated substantial efficacy as a second-line treatment for advanced RCC following progression on ICI-based therapies, with a tolerable safety profile. These findings reinforce cabozantinib as an important treatment option for patients progressing after ICI regimens. Clinical trial information: NCT04714697 .